Please login to the form below

Not currently logged in
Email:
Password:

Eloxatin

This page shows the latest Eloxatin news and features for those working in and with pharma, biotech and healthcare.

Sanofi predicts return to growth in second half

Sanofi predicts return to growth in second half

Sanofi is still weathering the effects of patent losses in 2012 for antiplatelet drug Plavix (clopidogrel), Avapro (irbesartan) for high blood pressure and cancer therapy Eloxatin (oxaliplatin) which collectively lost

Latest news

More from news
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...

Infographics